Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II.
Dopamine produced by renal proximal tubules increases sodium excretion via a decrease in renal sodium reabsorption. Dopamine natriuresis is impaired in obese Zucker rats; however, the mechanism is not fully understood. To test the hypothesis that renal expression of one or more of the subtypes are altered in these rats, we measured whole kidney protein levels by immunoblotting of D1-like (D1R and D5R) and D2-like (D2R, D3R, and D4R) dopamine receptors in both male and female obese and lean Zucker rats. In obese males on 1% NaCl diet, D1R, D2R, D4R, and D5R were decreased, while D3R was increased, relative to lean rats. Under a 4% NaCl diet, D2R and D3R levels in obese rats were restored to lean levels. 4% NaCl diet reduced D5R in both body types, relative to 1% NaCl diet. Female rats had higher expression of D1R and D3R than did male; however, the sex difference for D1R was markedly blunted in obese rats. In obese rats, dietary candesartan (angiotensin II type 1 receptor blocker) normalized downregulated D1R and D2R, but either decreased (D3R), did not affect (D4R), or further downregulated (D5R) the other subtypes. Candesartan also decreased D4R in lean rats. In summary, reduced renal protein levels of D1R, D2R, D4R, and D5R in obese Zucker rats could induce salt sensitivity and elevate blood pressure. Increased angiotensin II type 1 receptor activity may be mechanistically involved in the decreased expression of D1R and D2R in obese rats. Finally, reduced D1R and D3R in male rats may contribute to sex differences in blood pressure.
Wang
Xiaoyan
X
Bldg D, Rm 392, Georgetown Univ., 4000 Reservoir Rd NW, Washington, DC 20007, USA.
Li
Fengmin
F
Jose
Pedro A
PA
Ecelbarger
Carolyn M
CM
D000804:Angiotensin II / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D015153:Blotting, Western; D001823:Body Composition / Q000502:physiology; D004032:Diet; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D011954:Receptors, Dopamine / Q000096:biosynthesis*; D012727:Sex Characteristics; D017673:Sodium Chloride, Dietary / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011954:Receptors, Dopamine; D017673:Sodium Chloride, Dietary; D013777:Tetrazoles; D000804:Angiotensin II; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; C081643:candesartan
J Clin Invest. 1996 May 15;97(10):2283-8
8636408
Kidney Int. 2004 Dec;66(6):2167-80
15569306
J Clin Invest. 1998 Aug 1;102(3):493-8
9691085
Am J Physiol. 1992 Sep;263(3 Pt 2):R631-8
1357983
Hypertension. 2005 Apr;45(4):804-10
15699451
Neuroimage. 2008 Oct 1;42(4):1537-43
18598772
Hypertension. 1990 Jun;15(6 Pt 1):560-9
1971811
Clin Exp Hypertens. 2001 Nov;23(8):591-601
11728004
Curr Hypertens Rep. 2008 Aug;10(4):268-75
18625155
Hypertension. 1999 Nov;34(5):1091-6
10567187
Lab Invest. 2006 Mar;86(3):262-74
16402031
Clin Sci (Lond). 1988 Dec;75(6):569-75
2974769
Behav Brain Res. 2004 May 5;151(1-2):313-9
15084447
Am J Physiol. 1989 Sep;257(3 Pt 2):F469-77
2528916
Nutr Neurosci. 2002 Oct;5(5):321-6
12385594
Hypertension. 2003 Jun;41(6):1353-8
12707290
Brain Res Bull. 2008 Jan 31;75(1):70-6
18158098
Clin Exp Hypertens. 2003 Nov;25(8):509-15
14649308
J Neurosci. 2002 Dec 15;22(24):10801-10
12486173
Am J Clin Nutr. 1992 Nov;56(5):827-34
1415000
JAMA. 2002 Jan 16;287(3):356-9
11790215
FASEB J. 2008 Aug;22(8):2740-6
18477764
Hypertension. 1999 Apr;33(4):1036-42
10205244
Obes Res. 1993 Jan;1(1):5-17
16353346
Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R96-R104
16352863
Am J Physiol Renal Physiol. 2004 Jul;287(1):F109-16
15068975
Aviat Space Environ Med. 1996 Mar;67(3):248-52
8775403
Clin Exp Hypertens. 2000 Aug;22(6):635-44
10972167
Hypertension. 2002 Dec;40(6):880-5
12468573
Am J Physiol Renal Physiol. 2008 May;294(5):F1222-31
18305093
J Hum Hypertens. 2002 Mar;16 Suppl 1:S13-7
11986886
Gend Med. 2007 Sep;4(3):214-29
18022589
Neuroendocrinology. 2009;89(2):152-62
18984941
Eur J Pharmacol. 2003 Nov 7;480(1-3):125-31
14623356
Am J Physiol. 1998 Oct;275(4):R986-94
9756526
Clin Exp Hypertens A. 1992;14(4):615-28
1352742
Am J Hypertens. 1988 Jan;1(1):31-7
3285858
Handb Exp Pharmacol. 2005;(170):107-33
16596797
Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1071-8
11557612
Circulation. 2005 Apr 19;111(15):1962-9
15837950
Pediatr Nephrol. 2008 Dec;23(12):2131-46
18615257
Hypertension. 2000 Jan;35(1 Pt 2):403-8
10642332
J Clin Invest. 2008 Jun;118(6):2180-9
18464932
Diabetes. 2005 Jul;54(7):2219-26
15983225
Hypertens Res. 2007 Jan;30(1):93-101
17460376
Am J Physiol Renal Physiol. 2000 Jul;279(1):F46-53
10894786
Clin Exp Hypertens. 2009 Feb;31(1):49-63
19172459